Gombos, Andrea http://orcid.org/0000-0003-1664-2369
Venet, David
Ameye, Lieveke
Vuylsteke, Peter
Neven, Patrick
Richard, Vincent
Duhoux, Francois P. http://orcid.org/0000-0002-5429-7888
Laes, Jean-Francois
Rothe, Françoise
Sotiriou, Christos http://orcid.org/0000-0002-5745-9977
Paesmans, Marianne
Awada, Ahmad
Guiot, Thomas http://orcid.org/0000-0001-7041-598X
Flamen, Patrick
Piccart-Gebhart, Martine
Ignatiadis, Michail http://orcid.org/0000-0002-4493-3748
Gebhart, GĂ©raldine
Article History
Received: 12 March 2021
Accepted: 20 August 2021
First Online: 21 September 2021
Change Date: 16 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41523-022-00409-x
Competing interests
: Andrea Gombos: consulting fees: Lilly, Daiichi Sankyo; travel grants: Pfizer; none related to this paper. Patrick Neven: Astra Zeneca (consultancy), Eli Lilly (speaker fees, advisory board), Novartis (consultancy, advisory board, speaker fees), Pfizer (consultancy, speaker fees), Pierre Fabre (advisory board), Hoffmann/La Roche (consultancy, advisory board), Sanofi (research funding), Teva (advisory board); Travel grants: Astra Zeneca, Novartis, Pfizer, Hoffmann/La Roche. Francois P Duhoux: consulting fees: Pierre Fabre, Daiichi Sankyo; travel grants: Roche, Teva, Pfizer; none related to this paper. Christos Sotiriou: consulting fees: Astellas, Cepheid, Vertex, Seattle Genetics, Puma, Amgen, Merck; Participation in a company-sponsored speakers bureau: Eisai, Prime Oncology, Teva, Foundation Medicine, Genomic Health; travel grants: Roche, Genentech, Pfizer. Ahmad Awada: research grant for his institution: BMS, consulting fees, travel grants: Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, Astra Zeneca, Bayer, Leo Pharma, Merck, Daiichi Sankyo, Seattle Genetics. Michail Ignatiadis: research grant for his institution: Roche, Menarini Silicon Biosystems, Janssen Diagnostics, Pfizer; consulting fees: Celgene, Novartis, Pfizer, Seattle Genetics, Tesaro; travel grants: Pfizer, Amgen. Martine Piccart-Gebhart: Research grants to her institution: Astra Zeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon. Board Member (Scientific Board): Oncolytics; Consultant (honoraria): Astra Zeneca, Camel-IDS, Debiopharm, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Pfizer, Roche-Genentech, Seattle Genetics, Immutep; The other authors did not declare relevant competing interests.